Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Aug 1;13(4):1267-1278.
doi: 10.1093/advances/nmab149.

Effects of Microbiota-Driven Therapy on Circulating Indoxyl Sulfate and P-Cresyl Sulfate in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Li Chen  1   2   3 , Junhe Shi  1 , Xiaojuan Ma  1   3 , Dazhuo Shi  1   2   3 , Hua Qu  1   3   4
Affiliations
Meta-Analysis

Effects of Microbiota-Driven Therapy on Circulating Indoxyl Sulfate and P-Cresyl Sulfate in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Li Chen et al. Adv Nutr. .

Abstract

Indoxyl sulfate (IS) and p-cresyl sulfate (PCS), protein-bound uremic toxins, exacerbate the deterioration of renal function and increase the risk of cardiovascular events in chronic kidney disease (CKD) patients. The effects of microbiota-driven therapy (probiotics, prebiotics, or synbiotics) on decreasing circulating IS and PCS concentrations are controversial; thus, we performed the present systematic review and meta-analysis to assess the effects of microbiota-driven therapy on circulating IS and PCS concentrations in CKD patients. PubMed, EMBASE, and Cochrane Library databases were systematically searched from inception to 22 July, 2021, and randomized controlled trials (RCTs) investigating the effects of microbiota-driven therapy on circulating IS and PCS concentrations in CKD patients were included. In all, 14 RCTs with 513 participants were eligible for the meta-analysis. The effects of microbiota-driven therapy on the circulating IS and PCS concentrations were evaluated with weighted mean differences (WMDs) measured by a fixed-effects model or a random-effects model. Compared with placebo, microbiota-driven therapy had no statistically significant effect on the circulating IS concentration (WMD: -1.64 mg/L; 95% CI: -3.46, 0.18 mg/L; P = 0.077) but it decreased the circulating PCS concentration (WMD: -2.42 mg/L; 95% CI: -3.81, -1.04 mg/L; P = 0.001). In the subgroup analyses, prebiotic (n = 6) and synbiotic (n = 3) supplementation significantly decreased the circulating PCS concentration, whereas probiotic (n = 3) supplementation did not. Meta-regression showed that the effects of microbiota-driven therapy were not associated with the supplementation time or the year of publication. Moreover, there was no significant evidence of publication bias. This review found that microbiota-driven therapy decreased the circulating PCS concentration in CKD patients. Additional large, well-designed RCTs with improved methodology and reporting are necessary to assess the effects of microbiota-driven therapy on circulating IS and PCS concentrations in the long term. This systematic review was registered at www.crd.york.ac.uk/prospero/ as CRD42021269146.

Keywords: chronic kidney disease; indoxyl sulfate; meta-analysis; microbiota-driven therapy; p-cresyl sulfate.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Flow diagram for the study selection process. RCT, randomized controlled trial.
FIGURE 2
FIGURE 2
Risk of bias graph. Values are percentages.
FIGURE 3
FIGURE 3
Risk of bias summary.
FIGURE 4
FIGURE 4
Forest plot for circulating p-cresyl sulfate concentration: microbiota-driven therapy compared with placebo (fixed-effect model). WMD, weighted mean difference.
FIGURE 5
FIGURE 5
Meta-regression plot. (A, B) Change in PCS concentration according to (A) supplementation time of microbiota-driven therapy and (B) year of publication. (C, D) Change in IS concentration according to (C) supplementation time of microbiota-driven therapy and (D) year of publication. IS, indoxyl sulfate; PCS, p-cresyl sulfate.
FIGURE 6
FIGURE 6
Forest plot for circulating indoxyl sulfate concentration: microbiota-driven therapy compared with placebo (random-effect model). WMD, weighted mean difference.
FIGURE 7
FIGURE 7
Publication bias. (A) Funnel plot, (B) Begg test, and (C) Egger test for circulating IS concentration. (D) Funnel plot, (E) Begg test, and (F) Egger test for circulating PCS concentration. IS, indoxyl sulfate; PCS, p-cresyl sulfate; WMD, weighted mean difference.
See this image and copyright information in PMC

Comment in

References

    1. Gryp T, De Paepe K, Vanholder R, Kerckhof F-M, Van Biesen W, Van de Wiele T, Verbeke F, Speeckaert M, Joossens M, Couttenye MMet al. . Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease. Kidney Int. 2020;97(6):1230–42. - PubMed
    1. Meijers B, Evenepoel P, Anders HJ. Intestinal microbiome and fitness in kidney disease. Nat Rev Nephrol. 2019;15(9):531–45. - PubMed
    1. Tanaka K, Watanabe T, Takeuchi A, Ohashi Y, Nitta K, Akizawa T, Matsuo S, Imai E, Makino H, Hishida Aet al. . Cardiovascular events and death in Japanese patients with chronic kidney disease. Kidney Int. 2017;91(1):227–34. - PubMed
    1. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889):339–52. - PubMed
    1. Wang Z, Zhao Y. Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell. 2018;9(5):416–31. - PMC - PubMed

Publication types